<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Cell and Gene Therapy

Research    Funding    Awards    Cell and Gene Therapy

Project to Rev Up Cancer-Fighting Cells Wins Anschutz Acceleration Initiative Grant

A project to develop a way to boost the effectiveness of cellular cancer therapies, led by the University of Colorado Cancer Center’s Associate Director of Cancer Research Training and Education Coordination, Eduardo Davila, PhD, is one of nine research endeavors by CU School of Medicine faculty members to be awarded major funding from the Anschutz Acceleration Initiative.


Author Mark Harden | Publish Date February 02, 2024
Full Story

CU Cancer Center In the News

MHealthIntelligence

Leveraging RPM to Enable At-Home Care for High-Risk Cancer Patients

news outletMHealthIntelligence
Publish DateFebruary 05, 2024

Glen Peterson, DNP, ACNP, RN, from CU Cancer Center, discusses RPM & telehealth benefits for cancer patients on Healthcare Strategies podcast.

Full Story
9News

Sunday is World Cancer Day

news outlet9News
Publish DateFebruary 04, 2024

CU Anschutz oncologist and CU Cancer Center member Dr. Wells Messersmith shares insights: Colorado braces for over 29,000 cancer cases in the coming year.

Full Story
Cure Today

An Oncologist Explains How She Uses ctDNA in Gastric Cancer

news outletCure Today
Publish DateJanuary 24, 2024

CU Cancer Center member Sunnie Kim, MD, discussed how she uses ctDNA in treating patients with gastric or esophageal cancer.

Full Story
DocWire News

Toxicities and Duration of Treatment for Immunotherapy in Advanced Metastatic Hepatocellular Carcinoma

news outletDocWire News
Publish DateJanuary 23, 2024

CU Cancer Center member Christopher Lieu, MD, and Namrata Vijayvergia, MD, of the Fox Chase Cancer Center conclude their discussion with considerations for managing immunotherapy-related toxicities in patients with metastatic hepatocellular carcinoma (HCC), along with a review of the available evidence regarding the duration of immunotherapy treatment.

Full Story